Jack W. Callicutt
2018
In 2018, Jack W. Callicutt earned a total compensation of $1.3M as Chief Financial Officer at Galectin Therapeutics, a 212% increase compared to previous year.
Compensation breakdown
| Bonus | $213,750 |
|---|---|
| Option Awards | $715,319 |
| Salary | $275,278 |
| Other | $62,150 |
| Total | $1,266,497 |
Callicutt received $715.3K in option awards, accounting for 56% of the total pay in 2018.
Callicutt also received $213.8K in bonus, $275.3K in salary and $62.2K in other compensation.
Rankings
In 2018, Jack W. Callicutt's compensation ranked 8,014th out of 14,244 executives tracked by ExecPay. In other words, Callicutt earned more than 43.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,014 out of 14,244 | 44th |
Division Manufacturing | 3,154 out of 5,765 | 45th |
Major group Chemicals And Allied Products | 1,176 out of 2,128 | 45th |
Industry group Drugs | 988 out of 1,817 | 46th |
Industry Pharmaceutical Preparations | 767 out of 1,391 | 45th |
Source: SEC filing on October 19, 2020.
Callicutt's colleagues
We found one more compensation record of an executive who worked with Jack W. Callicutt at Galectin Therapeutics in 2018.
2018
Harold Shlevin
Galectin Therapeutics
Chief Executive Officer
News
Galectin Therapeutics CEO Joel Lewis' 2023 pay slips 1% to $964K
December 3, 2024
Galectin Therapeutics CEO Joel Lewis' 2022 pay slips 17% to $974K
October 6, 2023
Galectin Therapeutics CEO Joel Lewis' 2021 pay jumps 55% to $1.2M
October 17, 2022
Galectin Therapeutics CEO Harold Shlevin's 2019 pay falls 25% to $1.3M
October 19, 2020